A combination of robust operational performance and a decisive technical breakout is fueling renewed investor confidence in Bachem Holding AG. The peptide specialist, having concluded a strong fiscal year, is now channeling its focus toward an extensive capital investment plan and aggressive growth targets for the current period.
Financial Performance Lays the Foundation
The company’s recent financial results provide the core rationale for the upbeat market sentiment. Bachem reported group sales of CHF 695.1 million for the past year, with net profit surging by nearly a quarter to CHF 148.8 million. An EBITDA margin of 30.9% further highlights the firm’s underlying profitability. Under the leadership of its new CEO, Anne-Kathrin Stoller, management has set ambitious goals, targeting currency-adjusted sales growth of 35% to 45% for 2026.
Chart Analysis Indicates Strengthening Trend
From a technical perspective, the equity has issued a clear bullish signal. A sustained move above the 50-day moving average, currently positioned at GBP 63.25, has solidified the medium-term upward trend. The share price has advanced approximately 14% over the last 30 trading days, extending its distance from the 52-week low to a notable 36.9%. This display of relative strength against the Swiss healthcare sector follows a period of operational consolidation.
Should investors sell immediately? Or is it worth buying Bachem?
Capacity Expansion Through Significant Capex
To support its growth ambitions, Bachem is undertaking substantial investment in global infrastructure. Capital expenditures (CAPEX) are projected to rise to over CHF 400 million in 2026, up from CHF 332.6 million in the prior year. A central component of this strategy is the new “Building K” at the Bubendorf site. The first phase of this major project has already passed inspection successfully, and the gradual ramp-up of commercial production is viewed as critical for achieving annual objectives.
The coming months will be pivotal for the capacity expansion. Should the stock defend its current buffer of roughly 5.6% above the 50-day average, the technical outlook remains constructive for a potential test of the 52-week high at GBP 74.63. Market participants will closely watch the company’s progress toward its ambitious first-half sales forecast as a key benchmark for the new executive leadership.
Key Dates for Shareholders:
- 29 April 2026: Annual General Meeting, including a vote to increase the dividend to CHF 0.90
- 06 May 2026: Planned dividend payment date
- 30 July 2026: Publication of the 2026 Half-Year Report
Ad
Bachem Stock: Buy or Sell?! New Bachem Analysis from April 3 delivers the answer:
The latest Bachem figures speak for themselves: Urgent action needed for Bachem investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 3.
Bachem: Buy or sell? Read more here...
